Prognostic and Predictive Value of Pan-Immune Inflammation Value in Rectal Cancer Patients Treated With Neoadjuvant Therapy
Introduction Predicting prognosis before treatment in rectal cancer patients undergoing neoadjuvant therapy is essential for effective treatment strategy selection. This study evaluates the prognostic impact of the pretreatment pan-immune-inflammation value (PIV) on pathological response, local cont...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2025-07-01
|
| Series: | Cancer Control |
| Online Access: | https://doi.org/10.1177/10732748251361684 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850104676886773760 |
|---|---|
| author | Aybala Nur Ucgul MD Ismail Kaan Sert MD Huseyin Bora MD |
| author_facet | Aybala Nur Ucgul MD Ismail Kaan Sert MD Huseyin Bora MD |
| author_sort | Aybala Nur Ucgul MD |
| collection | DOAJ |
| description | Introduction Predicting prognosis before treatment in rectal cancer patients undergoing neoadjuvant therapy is essential for effective treatment strategy selection. This study evaluates the prognostic impact of the pretreatment pan-immune-inflammation value (PIV) on pathological response, local control, and overall survival. Methods We included 126 patients who received neoadjuvant treatment for rectal cancer from November 2020 to May 2024. This study was conducted retrospectively. PIV was calculated as (neutrophil count × platelet count × monocyte count)/lymphocyte count, with an optimal threshold identified at 475. Patients were categorized into low (PIV < 475) and high (PIV ≥ 475) groups. Pathological responses were analyzed using the chi-square test, while survival rates were assessed with the Kaplan-Meier method and log-rank tests. Cox regression analysis examined the influence of variables on outcomes. Results The high PIV group had a significantly higher prevalence of N2 disease (33.3% vs 13.7%, P = .02) and a greater incidence of abdominoperineal resection (35.9% vs 17.2%, P = .02). Pathological response was notably higher in the low PIV group (75% vs 33.3%, P < .001). Overall survival and local recurrence-free survival rates were significantly better in the low PIV group ( P = .006 and P = .004, respectively). In multivariate analysis, PIV was the only significant factor affecting overall and local recurrence-free survival. Conclusion Higher pretreatment PIV values correlate with poorer pathological response and reduced overall and local recurrence-free survival in rectal cancer patients. These findings support the use of PIV for risk stratification and treatment personalization. |
| format | Article |
| id | doaj-art-f58d6ce1d84e44e49f7da569bf5956c0 |
| institution | DOAJ |
| issn | 1526-2359 |
| language | English |
| publishDate | 2025-07-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Cancer Control |
| spelling | doaj-art-f58d6ce1d84e44e49f7da569bf5956c02025-08-20T02:39:16ZengSAGE PublishingCancer Control1526-23592025-07-013210.1177/10732748251361684Prognostic and Predictive Value of Pan-Immune Inflammation Value in Rectal Cancer Patients Treated With Neoadjuvant TherapyAybala Nur Ucgul MDIsmail Kaan Sert MDHuseyin Bora MDIntroduction Predicting prognosis before treatment in rectal cancer patients undergoing neoadjuvant therapy is essential for effective treatment strategy selection. This study evaluates the prognostic impact of the pretreatment pan-immune-inflammation value (PIV) on pathological response, local control, and overall survival. Methods We included 126 patients who received neoadjuvant treatment for rectal cancer from November 2020 to May 2024. This study was conducted retrospectively. PIV was calculated as (neutrophil count × platelet count × monocyte count)/lymphocyte count, with an optimal threshold identified at 475. Patients were categorized into low (PIV < 475) and high (PIV ≥ 475) groups. Pathological responses were analyzed using the chi-square test, while survival rates were assessed with the Kaplan-Meier method and log-rank tests. Cox regression analysis examined the influence of variables on outcomes. Results The high PIV group had a significantly higher prevalence of N2 disease (33.3% vs 13.7%, P = .02) and a greater incidence of abdominoperineal resection (35.9% vs 17.2%, P = .02). Pathological response was notably higher in the low PIV group (75% vs 33.3%, P < .001). Overall survival and local recurrence-free survival rates were significantly better in the low PIV group ( P = .006 and P = .004, respectively). In multivariate analysis, PIV was the only significant factor affecting overall and local recurrence-free survival. Conclusion Higher pretreatment PIV values correlate with poorer pathological response and reduced overall and local recurrence-free survival in rectal cancer patients. These findings support the use of PIV for risk stratification and treatment personalization.https://doi.org/10.1177/10732748251361684 |
| spellingShingle | Aybala Nur Ucgul MD Ismail Kaan Sert MD Huseyin Bora MD Prognostic and Predictive Value of Pan-Immune Inflammation Value in Rectal Cancer Patients Treated With Neoadjuvant Therapy Cancer Control |
| title | Prognostic and Predictive Value of Pan-Immune Inflammation Value in Rectal Cancer Patients Treated With Neoadjuvant Therapy |
| title_full | Prognostic and Predictive Value of Pan-Immune Inflammation Value in Rectal Cancer Patients Treated With Neoadjuvant Therapy |
| title_fullStr | Prognostic and Predictive Value of Pan-Immune Inflammation Value in Rectal Cancer Patients Treated With Neoadjuvant Therapy |
| title_full_unstemmed | Prognostic and Predictive Value of Pan-Immune Inflammation Value in Rectal Cancer Patients Treated With Neoadjuvant Therapy |
| title_short | Prognostic and Predictive Value of Pan-Immune Inflammation Value in Rectal Cancer Patients Treated With Neoadjuvant Therapy |
| title_sort | prognostic and predictive value of pan immune inflammation value in rectal cancer patients treated with neoadjuvant therapy |
| url | https://doi.org/10.1177/10732748251361684 |
| work_keys_str_mv | AT aybalanurucgulmd prognosticandpredictivevalueofpanimmuneinflammationvalueinrectalcancerpatientstreatedwithneoadjuvanttherapy AT ismailkaansertmd prognosticandpredictivevalueofpanimmuneinflammationvalueinrectalcancerpatientstreatedwithneoadjuvanttherapy AT huseyinboramd prognosticandpredictivevalueofpanimmuneinflammationvalueinrectalcancerpatientstreatedwithneoadjuvanttherapy |